• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Consumer Cyclical·2269.T
Share

Meiji Holdings Co., Ltd. Stocks

¥ 4381Last Updated 13.11.2026

Issuer Rating

6/7
Performance

Average

Risk

Low

Recommendation

Buy

Market Cap

¥ 7.21B

¥ 4381
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Decent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Meiji Holdings Co., Ltd., established in Tokyo, Japan, in 1916, operates globally as a prominent manufacturer and seller across two core business segments: Food and Pharmaceutical. Its extensive Food division produces and markets a wide array of products, including various dairy items like yogurts, milk, cheeses, butter, and ice cream. This segment also encompasses a diverse selection of confectioneries, such as chocolates, gummy treats, and candies, alongside nutritional offerings like sports supplements, infant formulas, and beauty aids. Further contributions from the Food sector include frozen foods, sugar, over-the-counter medications, and livestock products, complemented by essential transportation and distribution services. The Pharmaceutical segment is dedicated to the development and provision of human health solutions, specifically targeting infectious diseases and central nervous system disorders, as well as manufacturing generic drugs, human and animal vaccines, and blood plasma products. Additionally, this division supplies a comprehensive range of veterinary medicines for livestock, fisheries, and companion animals, covering antimicrobials, pain relief, anti-inflammatory agents, and specialized treatments, alongside agricultural and livestock chemicals.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 2269.T is 4375 and suggests 1.21% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.11.2026 03:32

SpaceX has successfully caught Starship with its capture tower for the first time. What does this mean for the stock?

14.11.2026 17:01

What's New in Small-Cap Stocks: The Forbes Ranking, Oklo's Plans for Meta, and Ceco's Record

14.11.2026 13:01

Is There Life After Huang? The Rise of Anthropic, and the AI Rally in the Clouds

14.11.2026 04:56

Key Starship tests did not go as planned. SpaceX shares fell

14.11.2026 04:35

The S&P 500 posted its best week in six months. Barclays expects growth for the first time since March

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026